Paul Sack, MD
Endocrinology, Diabetes & Metabolism · Baltimore, MDNPI 1598707606
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $5,000 of the $8,049 with a category attached, or 62.1%. Abbott accounts for 62.7% of it on its own, with 30 other manufacturers making up the rest. Reporting peaked in 2020 at $5,117 and has fallen 68.3% since, to $1,621 in 2024.
Across 66 payments — averaging $121.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$5K
- Novo Nordisk$2K
- Sanofi-aventis U.S. LLC$132
- BETA Bionics, Inc.$125
- Dexcom, Inc.$118
- Lilly USA, LLC$103
- plus $776 from 25 others
Across 22 payments — averaging $2786.92 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- IBSA Institut Biochimique SA$48K
- Takeda Pharmaceuticals U.S.A., Inc.$13K
What the payments were for
- Consulting fees$1,57520%
- Speaking & faculty fees$5,00062%
- Food & beverage$1,40617%
- Education$681%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 3 | $5,048 |
| Novo Nordisk | 11 | $1,747 |
| Sanofi-aventis U.S. LLC | 5 | $132 |
| BETA Bionics, Inc. | 2 | $125 |
| Dexcom, Inc. | 3 | $118 |
| Lilly USA, LLC | 5 | $103 |
| Boehringer Ingelheim | 4 | $78 |
| Xeris Pharmaceuticals, Inc. | 3 | $65 |
| Recordati_rare_diseases_inc. | 3 | $60 |
| Valeritas, Inc. | 2 | $54 |
| Amgen(2 entities) | 2 | $45 |
| Bayer | 2 | $39 |
| AbbVie | 2 | $37 |
| Insulet Corporation | 1 | $37 |
| Novartis | 1 | $31 |
| Lifescan, Inc. | 2 | $31 |
| Radius Health, Inc. | 1 | $29 |
| Corcept Therapeutics | 1 | $27 |
| Acerus Pharmaceuticals Corporation | 1 | $26 |
| Kyowa Kirin, Inc. | 1 | $23 |
| Amarin Pharma, Inc. | 1 | $22 |
| Esperion Therapeutics, Inc. | 1 | $21 |
| Cequr Corporation | 1 | $20 |
| Ipsen Biopharmaceuticals, Inc | 1 | $19 |
| Shire North American Group Inc | 1 | $19 |
| Gilead | 1 | $18 |
| Zealand Pharma US, Inc. | 1 | $17 |
| Johnson & Johnson | 1 | $16 |
| Medtronic | 1 | $16 |
| AstraZeneca | 1 | $14 |
| Companion Medical, Inc. | 1 | $13 |
How this compares
$8,049 in reported general payments places this provider in the 80th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
See all endocrinology, diabetes & metabolism providers in Maryland →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 266 | $385,309 |
| OzempicSemaglutide | 212 | $347,876 |
| TrulicityDulaglutide | 172 | $292,199 |
| Tresiba Flextouch U-200Insulin Degludec | 83 | $129,442 |
| JardianceEmpagliflozin | 93 | $123,088 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 48 | $97,591 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 37 | $77,960 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 40 | $74,193 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 55 | $70,906 |
| FarxigaDapagliflozin Propanediol | 34 | $53,773 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 30 | $49,685 |
| Tresiba Flextouch U-100Insulin Degludec | 67 | $48,851 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 31 | $46,682 |
| Xigduo XrDapaglifloz Propaned/Metformin | 52 | $45,441 |
| JanuviaSitagliptin Phosphate | 23 | $32,884 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $103 | $689,592474 claims |
| Novo NordiskOzempic, Xultophy 100-3.6, Tresiba, Novolog | $1,747 | $441,567294 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $78 | $193,994148 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $132 | $97,59148 claims |
| AstraZenecaFarxiga | $14 | $53,77334 claims |
| Esperion Therapeutics, Inc.Nexletol | $21 | $11,60619 claims |
| AbbVieSynthroid | $37 | $5,15066 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
Other endocrinology, diabetes & metabolism in Baltimore
- Philip LevinBaltimore$489K
- Adrian DobsBaltimore$149K
- Todd BrownBaltimore$143K
- Roberto SalvatoriBaltimore$53K
- Nowreen HaqBaltimore$40K
- Asif MohamedBaltimore$31K
- Sherita GoldenBaltimore$27K
- Jean ParkBaltimore$13K
- Mansur ShomaliBaltimore$11K
- Malek CheikhBaltimore$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.